Serum and urine TNF-like weak inducer of apoptosis,monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus

Abstract

Objectives

TNF-like weak inducer of apoptosis (TWEAK), monocyte chemoattractant protein-1 (MCP-1) and neutrophil gelatinase-associated lipocalin (NGAL) are proinflammatory cytokines/chemokines that are considered as potential biomarkers reflecting disease activity in systemic lupus erythematosus (SLE). In this study, we aimed to investigate the association of serum (s) and urine (u) levels of TWEAK, MCP-1 and NGAL with disease activity in both renal and extra-renal SLE.

Methods

Thirty active patients with SLE (15 renal and 15 extra-renal) were recruited. Thirty-one inactive patients with SLE (16 renal and 15 extra-renal), 14 patients with ANCA-associated vasculitis (AAV) all of whom had active renal involvement and 20 healthy volunteers were selected as control groups. Serum and urine levels of TWEAK, MCP-1 and NGAL were tested using ELISA.

Results

Serum and urine levels of TWEAK and NGAL were significantly higher in the active SLE group compared to the inactive SLE group (sTWEAK p = 0.005; uTWEAK p = 0.026; sNGAL p < 0.001; uNGAL p = 0.002), whilst no significant differences regarding serum and urine MCP-1 levels were observed (p = 0.189 and p = 0.106, respectively). uTWEAK (p = 0.237), sMCP-1 (p = 0.141), uMCP-1 (p = 0.206), sNGAL (p = 0.419) and uNGAL (p = 0.443) levels did not differ between patients with active renal and extra-renal SLE. Serum TWEAK was higher in patients with active renal SLE (p = 0.006). There were no differences between active renal SLE and active renal AAV. Levels of all biomarkers were correlated with the SLE Disease Activity Index.

Conclusion

sTWEAK, uTWEAK, sNGAL and uNGAL are biomarkers showing disease activity in SLE. However, our results implicate that these biomarkers may not be specific for SLE, and can be elevated in patients with active renal involvement of AAV.

Keywords

Systemic lupus erythematosus lupus nephritis biomarkers TWEAK MCP-1 NGAL ANCA-associated vasculitis

Get full access to this article

View all access options for this article.

References

Ugarte-Gil

Alarcon

History of systemic lupus erythematosus. In: Gordon

Isenberg

(eds). Systemic lupus erythematosus, 1st ed. Oxford: Oxford University Press 2016, pp. 1–6.

Rahman

Isenberg

. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929–939.

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.

Arriens

Wren

Munroe

Mohan

. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 2017; 56: i32–i45.

Mok

. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010; 2010: 638413–638413.

Piñeiro

Arrizabalaga

Solé

Abellana

Espinosa

Cervera

. Repeated renal biopsy – a predictive tool to assess the probability of renal flare in lupus nephritis. Am J Nephrol 2016; 44: 439–446.

Gómez-Puerta

Ortiz-Reyes

Urrego

, et al. Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients. Lupus 2018; 27: 637–646.

Mok

. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006; 36: 71–81.

Yap

Tang

Lam

Chan

. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 3248–3254.

10.

Schwartz

Rubinstein

Burkly

, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11: R143–R143.

11.

Rubinstein

Pitashny

Levine

, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010; 49: 960–971.

12.

El-Shehaby

Darweesh

El-Khatib

, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31: 848–856.

13.

Kiani

Fang

, et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol 2012; 39: 1231–1237.

14.

Torres-Salido

Cortes-Hernandez

Vidal

, et al. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrol Dial Transplant 2014; 29: 1740–1749.

15.

Choe

Kim

. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus. Inflamm Res 2016; 65: 479–488.

16.

Gupta

Yadav

Aggarwal

. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity. Clin Rheumatol 2016; 35: 2707–2714.

17.

Landolt-Marticorena

Prokopec

Morrison

, et al. A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Res Ther 2016; 18: 218–218.

18.

Sun

Teng

Chang

. Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis. Exp Ther Med 2018; 15: 2611–2619.

19.

Živković

Cvetković

Mitić

, et al. Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study. Rheumatol Int 2018; 38: 1003–1008.

20.

Reyes-Martinez

Pérez-Navarro

Rodriguez-Matias

, et al. Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: an exploratory study. Nefrologia 2018; 38: 152–160.

21.

Petri

Orbai

Alarcon

, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

22.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

23.

Gladman

Urowitz

Goldsmith

, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809–813.

24.

Petri

Kim

Kalunian

, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

25.

Jennette

Falk

Bacon

, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1–11.

26.

Levey

Stevens

Schmid

, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

27.

Weening

D’Agati

Schwartz

, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.

28.

World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–926.

29.

Hiramatsu

Kuroiwa

Ikeuchi

, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford) 2008; 47: 702–707.

30.

Schwartz

Burkly

, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27: 242–250.

31.

Illei

Tackey

Lapteva

Lipsky

. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048–2065.

32.

Davis

Hutcheson

Mohan

. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 781–789.

33.

Abujam

Cheekatla

Aggarwal

. Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 2013; 22: 614–623.

34.

El Shahawy

Hemida

Abdel-Hafez

El-Baz

Lotfy

Emran

. Urinary neutrophil gelatinase-associated lipocalin as a marker for disease activity in lupus nephritis. Scand J Clin Lab Invest 2018; l78: 264–268.

35.

Ortiz

Sanz

Muñoz Garcia

, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20: 251–258.

36.

Schwartz

Michaelson

Putterman

. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007; 1109: 265–274.

37.

Campbell

Burkly

Gao

, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006; 176: 1889–1898.

38.

Gao

Campbell

Burkly

, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46: 24–35.

39.

Chakraborty

Kaur

Guha

Batra

. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012; 1826: 129–169.

40.

Weidner

Geuss

Hafezi-Rachti

Wonka

Rupprecht

. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403–1411.

41.

Satirapoj

Kitiyakara

Leelahavanichkul

Avihingsanon

Supasyndh

. Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis. BMC Nephrol 2017; 18: 263–263.

42.

Tang

Toh

Teo

. Normalisation of urinary biomarkers to creatinine for clinical practice and research – when and why. Singapore Med J 2015; 56: 7–10.

43.

Waikar

Sabbisetti

Bonventre

. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010; 78: 486–494.

44.

Thurman

Wong

Renner

, et al. Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 2015; 10: e0136558–e0136558.

45.

Ntatsaki

Watts

Scott

. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010; 36: 447–461.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB